Colorectal Cancer: Isofol’s Modufolin Could Change Mainstay Therapy
Executive Summary
Decades-long academic and pharma research to improve on the benefits of the 5-fluorouracil and Leucovorin combination in colorectal cancer has reached a crucial point, with a multinational Phase III pivotal trial of Isofol’s Modufolin being cleared by regulators but funding is still needed.
You may also be interested in...
For Roche Immuno-Oncology, It’s Steady As She Goes
Roche’s oncology R&D juggernaut gains momentum with surge of combination trials around cancer immunotherapy, illustrated in an animated chart. But the company is keeping its focus on systematically building a base of randomized clinical data to back up efficacy signals for PD-L1 inhibitor Tecentriq
Pipeline Watch: Phase III Readouts In Cervical Cancer, COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lundbeck's Migraine Therapy Vyepti: Overcoming The COVID-19 Effect
Denmark’s Lundbeck is aiming to build up use of its latest neurological, the long-acting migraine preventative, Vyepti, now that US healthcare is emerging from COVID-19-related restrictions, but is facing headwinds from loss of exclusivity on Northera.